<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022425</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068816</org_study_id>
    <secondary_id>CCF-IRB-3574</secondary_id>
    <secondary_id>CCF-N01-CN-55131</secondary_id>
    <secondary_id>NCI-P01-0189</secondary_id>
    <nct_id>NCT00022425</nct_id>
  </id_info>
  <brief_title>Perillyl Alcohol in Preventing Recurrent Breast Cancer in Women Who Have Been Treated With Surgery With or Without Adjuvant Therapy</brief_title>
  <official_title>Multiple-Dose Phase I and Pharmacokinetic Trial of Perillyl Alcohol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      recurrence of cancer. The use of perillyl alcohol may be effective in preventing the&#xD;
      recurrence of breast cancer.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of perillyl alcohol in preventing the&#xD;
      recurrence of breast cancer in women who have been treated with surgery with or without&#xD;
      adjuvant therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of perillyl alcohol in women at risk for recurrent&#xD;
           breast cancer.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine the single-dose and multiple-dose pharmacokinetics of this drug in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive oral perillyl alcohol once daily on days 1-28. Treatment continues every 4&#xD;
      weeks for 3 courses.&#xD;
&#xD;
      Cohorts of 6 patients receive escalating doses of perillyl alcohol until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at&#xD;
      least 2 of 6 patients experience grade 1 toxicity or at least 1 of 6 patients experience&#xD;
      grade 2 or greater toxicity.&#xD;
&#xD;
      Patients are followed weekly.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2001</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perillyl alcohol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Personal history of stage Tis, I, II, or IIIA breast cancer&#xD;
&#xD;
          -  Previously treated with definitive resection with curative intent&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No known malabsorption syndrome&#xD;
&#xD;
          -  No contraindication to perillyl alcohol&#xD;
&#xD;
          -  No hypersensitivity to citrus or soybean products&#xD;
&#xD;
          -  No non-breast malignancy within the past 2 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ&#xD;
&#xD;
          -  No active malignancy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 6 months since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent adjuvant hormonal therapy allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 months since prior surgery&#xD;
&#xD;
          -  At least 2 years since prior primary surgery&#xD;
&#xD;
          -  More than 4 weeks since prior surgery requiring general anesthesia, including breast&#xD;
             reconstructive surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  More than 3 months since prior enrollment in a single-dose study of perillyl alcohol&#xD;
&#xD;
          -  More than 3 months since prior enrollment in current study (at a lower dose level)&#xD;
&#xD;
          -  No concurrent vitamin supplements except a daily multivitamin (recommended daily&#xD;
             allowance)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Thomas Budd, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195-9001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2003</verification_date>
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Perillyl alcohol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

